Boehringer to acquire NBE-Therapeutics for $1.43bn
This deal will enhance Boehringer’s focus on targeted cancer cell-directed therapies. Credit: Remaztered Studio from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
